McKesson (MCK) has investors rechecking the story after its second quarter update, with sales of US$110.96b and net income of US$1.22b helping frame the latest move in the stock.
At a share price of US$1,091.67, McKesson has cooled slightly in the last session with a 1-day share price return that declined 1.21%. However, the 30-day share price return of 8.64% and 90-day gain of 27.87% point to momentum that has been building through recent earnings and upbeat research coverage, supported by longer term total shareholder returns of 27.33% over 1 year and very strong compounding over 3 and 5 years.
See how McKesson fits alongside other healthcare distributors with strong balance sheets and consistent fundamentals using our hand picked list of solid balance sheet and fundamentals (24 results)
McKesson keeps putting up solid operating results while sentiment around the stock has clearly warmed. How much of the recent share price climb already reflects that reality in valuation terms?
The analyst consensus Narrative on Simply Wall St puts McKesson’s fair value at $1,144.29, slightly above the latest close of $1,091.67. This frames the recent share price strength against a modest valuation gap built on detailed earnings and revenue forecasts.
Analysts expect earnings to reach $6.5 billion (and earnings per share of $60.89) by about November 2029, up from $4.7 billion today. The analysts are largely in agreement about this estimate.
See why 67 investors see McKesson as 5% undervalued.
Result: Fair Value of $1,144.29 (UNDERVALUED)
Still, the bullish McKesson story can be shaken if drug pricing reforms pressure already thin margins, or if cyber and data security costs start to bite into earnings.
Find out about the key risks to this McKesson narrative.
There is a catch. McKesson screens as undervalued on future cash flows, yet on a straight P/E it looks expensive at 26.8x versus 25.1x for the US Healthcare group and 21.6x for peers, even though the fair ratio sits higher at 34.3x. Is the market already paying up, or still catching up?
To see how that gap between today’s multiple, peers, and the fair ratio could close, and what it might mean for future upside or downside risk, See what the numbers say about this price — find out in our valuation breakdown.
Mixed messages in the McKesson story, with both risk flags and reward signals in play, mean your own read of the numbers really matters. If you want a quick way to weigh both sides of the ledger in one place, take a look at the 3 key rewards and 1 important warning sign
If McKesson has sharpened your focus, you can use that momentum and scan fresh opportunities with clear data, side by side, before the next move passes you by.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com